Appendix 1

RCR Clinical Oncology Syllabus

Sections

- 1. Common competences for clinical oncology
- 2. Introductory module
- 3. Oncological emergencies
- 4. Site-specific learning outcomes

List of abbreviations

Workplace-based assessments

CbD Case-Based Discussion

DORPS Directly Observed assessment of Radiotherapy Planning Skills
DOST Directly Observed assessment of Systemic Therapy skills

mini-CEX Mini-Clinical Evaluation Exercise

MSF Multi-Source Feedback

PS Patient Survey

Others

ARSAC Administration of Radioactive Substances Advisory Committee

BMA British Medical Association
DVH Dose volume histogram

FRCR Fellowship of the Royal College of Radiologists

GMC General Medical Council GMP Good medical practice

ICRU International Commission on Radiation Units and Measurements

IRMER Ionising Radiation (Medical Exposure) Regulations

MDT Multidisciplinary team

NCEPOD National Confidential Enquiry into Patient Outcome and Death

NHSMEE NHS Medical Education England

Domains of Good Medical Practice (GMP) Key

Ī	1	Knowledge, Skills and Performance	3	Communication, Partnership and Teamwork
Ī	2	Quality, Improvement and Safety	4	Maintaining Trust

It is expected that trainees will maintain knowledge, skills and behaviours previously learned and build on them as they progress through training, so that by CCT they will have developed all of the skills required to work as a consultant in clinical oncology. All of the knowledge, skills and behaviours acquired during intermediate clinical oncology training may be assessed in the Final FRCR examination.

The workplace-based assessment (WpBA) methods shown are those that are appropriate as **possible** methods that could be used to assess each competency. It is expected that competencies will be sampled for assessment and that a variety assessment methods will be used, i.e. it is not expected that all competencies will be assessed nor that where they are assessed, every method will be used. WpBAs should sample across the entire curriculum and be conducted in a timely manner throughout each clinical attachment (i.e. generally spread evenly through training and not all completed in the final weeks of an attachment). This document should be used in conjunction with the ARCP Decision Aid (Curriculum Section 5.5, p18)

1 Common competencies for clinical oncology

Underpinning attitudes and behaviours

Common competencies identified in this section are generic competencies that are required by clinical oncologists. They build upon each area of competence which a trainee has acquired during core medical training. It is recognised that for many of the competences outlined there is a maturation process whereby the doctor becomes more adept and skilled as his/her career and experience progresses.

All the clinical learning outcomes listed in this curriculum are underpinned by appropriate attitudes and behaviours. These are drawn from Good Medical Practice (GMP).

1.1 Personal behaviour

To demonstrate the behaviours that will enable the doctor to become a senior leader able to deal with complex situations and difficult behaviours and attitudes.

To work increasingly effectively with many teams and to be known to put the quality and safety of patient care as a prime objective

To demonstrate the attributes of someone who is trusted to be able to manage complex human, legal and ethical problem.

To be someone who is trusted and is known to act fairly in all situations

Knowledge	Assessment Methods	GMP
Defines the concept of modern medical professionalism	CbD	1
Outlines the relevance of professional bodies (Royal Colleges, NHSMEE, GMC, Postgraduate Deaneries, BMA, medical defence societies, etc)	CbD	1
Skills		
Practises with professionalism, showing: integrity compassion altruism continuous improvement aspiration to excellence respect of cultural and ethnic diversity regard to the principles of equity	CbD, mini-CEX, MSF, Patient Survey	1,2,4
Works in partnership with patients and members of the wider healthcare team	CbD, mini-CEX, MSF	3
Liaises with colleagues to plan and implement work rotas	MSF	3
Promotes awareness of the doctor's role in utilising healthcare resources optimally and within defined resource constraints	CbD, mini-CEX, MSF	1,3
Recognises and responds appropriately to unprofessional behaviour in others	CbD	1

Behaviour					
Recognises p	ersonal beliefs and biases and understand their impact y of health services	CbD, mini-CEX, MSF	1		
	ts on appropriately where personal beliefs and biases upon professional practice	CbD, mini-CEX, MSF	1		
Uses all healt	hcare resources prudently and appropriately	CbD, DOST, DORPS, mini-CEX	1,2		
Improves clin	ical leadership and management skill	CbD, mini-CEX	1		
Recognises s and regulator	ituations when it is appropriate to involve professional y bodies	CbD, mini-CEX	1		
Acts as a lead	der, mentor, educator and role model where appropriate	CbD, mini-CEX, MSF	1		
Continues to:		CbD, mini-CEX	1		
• De	eal with inappropriate patient and family behaviour				
	espect the rights of children, elderly, people with physical, ental, learning or communication difficulties				
pa	dopt an approach to eliminate discrimination against tients from diverse backgrounds including age, gender, ce, culture, disability, spirituality and sexuality				
• Pl	ace needs of patients above own convenience				
• Be	ehave with honesty and probity				
• Ac	ct with sensitivity in a non-confrontational manner				
Accepts ment professional of	oring as a positive contribution to promote personal development	CbD, mini-CEX, MSF	1		
Participates ir	n professional regulation and professional development	CbD, mini-CEX, MSF	1		
Takes part in	360 degree feedback as part of appraisal	CbD, MSF	1,2,4		
Promotes the	right for equity of access to healthcare	CbD, mini-CEX,	1		
Demonstrates team	s reliability and accessibility throughout the healthcare	CbD, mini-CEX, MSF	1		
Level Descrip	tors				
Intermediate	Responds to criticism positively and seeks to understand its origins and works to improve Praises staff when they have done well and where there are failings in delivery of care provides constructive feedback Comprehends when other staff are under stress and not performing as expected and provides appropriate support for them Takes action necessary to ensure that patient safety is not compromised				
	Engenders trust so that staff feel confident about sharing to point out deficiencies in care at an early stage	difficult problems and	feel able		
Advanced Helps patients who show anger or aggression works with them to find an approach to mana patient and the healthcare team					

1.2 Time management and decision making

To prioritise and organise clinical and clerical duties to optimise patient care and makes appropriate decisions to optimise the effectiveness of the clinical team.

decisions to optimize the check of the chimical tearn.				
Knowledge		Assessment Methods	GMP	
Illustrates the importance	need to prioritise work according to urgency and	CbD	1	
	roles, competences and capabilities of other and support workers	CbD	1	
Outlines techi	niques for improving time management	CbD	1	
	the importance of prompt investigation, diagnosis and atient management	CbD, mini-CEX	1,2	
Skills				
Maintains foci pressures	us on individual patient needs whilst balancing competing	CbD	1	
Organises an	d manages workload effectively and flexibly.	CbD, mini- CEX	1	
Makes approp	oriate use of other professionals and support workers	CbD, mini-CEX	1,3	
Behaviours				
Works flexibly	and deals with tasks in an effective and efficient fashion	CbD, MSF	3	
Recognises w rectify the situ	hen you or others are falling behind and take steps to ation	CbD, MSF	3	
Communicate	s changes in priority to others	DORPS, DOST, MSF	1	
Remains calm timely, rationa	n in stressful or high pressure situations and adopt a al approach	MSF	1	
Appropriately consultation	recognises and handles uncertainty within the	mini-CEX, MSF	1	
Level Descri	otors			
Completes work in a timely fashion Organises own work efficiently and supervises work of others Intermediate Recognises the most important tasks and responds appropriately Anticipates when priorities should be changed Starting to lead and direct the clinical team in effective fashion Supports others who are falling behind Requires minimal organisational supervision				
Advanced	Automatically prioritises, reprioritises and manages workload efficiently Takes responsibility for organising the clinical team			

1.3 Decision making and clinical reasoning

To develop the ability to formulate a diagnostic and therapeutic plan for a patient according to the clinical information available

To develop the ability to prioritise the diagnostic and therapeutic plan

To be able to communicate a diagnostic and therapeutic plan appropriately

Knowledge		Assessment Methods	GMP
Recognises the presentation	e psychological component of disease and illness	CbD, mini-CEX	1
Recognises ho algorithms	w to use expert advice, clinical guidelines and	CbD, mini-CEX	1
Recognises an accessed by p	nd appropriately responds to sources of information atients	CbD, mini-CEX	1
Skills			
	n understanding of the psychological and social nical scenarios into decision making through clinical	CbD, mini-CEX	1
	the need to determine the best value and most effective for the individual patient and for a patient cohort	CbD, mini-CEX	1
patient, carers	appropriate management plan in conjunction with the and other members of the clinical team and this effectively to the patient and carers where relevant	CbD, mini-CEX	1,3,4
Applies the rele individual patie	evance of an estimated risk of a future event to an	CbD, mmini-CEX	1,2
Searches and	comprehends medical literature to guide reasoning	Audit Asessment, CbD	1
Behaviours			
Recognises the	e difficulties in predicting occurrence of future events	CbD, mini-CEX	1
Shows willingn	ess to facilitate patient choice	CbD, mini-CEX	3
Shows willingn making	ess to search for evidence to support clinical decision	CbD, mini-CEX	1,4
Level Descrip	tors		
	Develops a provisional diagnosis and a differential diagnosis	nosis on the basis of the	clinical
Intermediate	Institutes an appropriate investigative plan		
	Institutes an appropriate therapeutic plan		
	Seeks appropriate support from others		
	Takes account of the patients wishes and records them	accurately and succinct	ily

1.4 The patient as central focus of care

To prioritise the patient's wishes encompassing their beliefs, concerns expectations and needs				
Knowledge		Assessment Methods	GMP	
and recognise	h needs of particular populations, e.g. ethnic minorities, s the impact of health beliefs, culture and ethnicity on of physical and psychological conditions	CbD	1	
Describes sou	rces of information and support for patients	MSF Patient Survey	3	
Skills				
	te time for patients and carers to express their beliefs and expectations	mini-CEX	1,3,4	
Ascertains the	desire of the patient for information	mini-CEX, MSF Patient survey	3	
Tailors the dis requirements	cussion and written information to the patients'	mini-CEX, MSF Patient Survey	2	
Supports patie management	ents and carers where relevant to comply with plans	mini-CEX, MSF, Patient Survey	1,2,3	
Encourages p about their car	atients to voice their preferences and personal choices re	mini-CEX, Patient Survey	3	
Behaviours				
Responds to d	questions honestly and seeks advice if unable to answer	CbD, mini-CEX	3	
Recognises the advocate	e duty of the medical professional to act as patient	CbD, mini-CEX, MSF, Patient Survey	3,4	
	s with respect and without discrimination, is polite, and honest, shows respect for dignity and privacy.	mini-CEX, MSF, Patient Survey	3,4	
Treats patient	s fairly and as individuals	mini-CEX, MSF, Patient Survey	3,4	
Encourages p to improve and	atients to take an interest in their health and take action d maintain it	mini-CEX, MSF, Patient Survey	2,3	
Level Descrip	otors			
Intermediate	Is sensitive to patients' cultural concerns and norms. Explains diagnoses and treatments in ways that enable patients to understand and make decisions about their own health care.			
Advanced	Advanced Discusses complex questions and uncertainties with patients and enables them to make decisions about difficult aspects of their health, e.g. to opt for no treatment or to make end of life decisions			

1.5 Patient safety

To prioritise patient safety throughout all clinical practice.			
Knowledge		Assessment Methods	GMP
Outlines the co	onditions required to maintain a safe working	CbD	1
Describes the cytotoxic drugs	toxicities of systemic therapies and safe handing of	First FRCR, CbD	1
Describes the frameworks an	principles of radiation protection, including statutory d local rules	First FRCR	1
Skills			
	leagues in the healthcare team to ensure that patient ed in a way that ensures patient safety	CbD	1
Recognises an response to the	d responds to a patient's deterioration or lack of erapy	CbD, mini-CEX, MSF	1,2
Improves patie associated with	nts' and colleagues understanding of the risks n treatment	CbD, mini-CEX	1,3
Ensures that p	rocedures for safe practice are followed	CbD, mini-CEX	1
Behaviours			
Maintains a hig	h level of safety awareness at all times	CbD, mini-CEX	2
	iate action when concerns are raised about own r that of colleagues	CbD, mini-CEX, MSF	3
Continues to b	e aware of own limitations and operates within these	CbD, mini-CEX	1
Level descrip	tors		
Assesses the risks across the system of care and works with colleagues from diffe department or sectors to ensure safety across the health care system.			different
Intermediate	Involves the whole clinical team in discussions about patient safety Shows support for junior colleagues who are involved in untoward events.		
Is fastidious about following safety protocols and ensures that junior colleagues do same. Is able to explain the rationale for protocols.			
Advanced	Demonstrates ability to lead an investigation of a serio and synthesise an analysis of the issues and plan for r		

1.6 Team Working

To develop the ability to work well in a variety of different teams

To develop leadership skills required to lead a team to be more effective and able to deliver better patient care

care				
Knowledge		Assessment Methods	GMP	
Describes the roles and responsibilities of members of the healthcare team		CbD	1	
	Outlines factors adversely affecting a doctor's and team performance and methods to rectify these		1	
Skills				
Practises with	attention to providing good continuity of care	CbD, mini-CEX	1,3,4	
	ate attributable patient notes, including appropriate use of cal record systems	CbD, mini-CEX	1,3	
Delivers detaile	ed hand over between shifts and areas of care	CbD, mini-CEX , MSF	1,3	
Demonstrates	leadership and management in the following areas:	CbD, mini-CEX,	1,2,3	
Coordi	nates and leads a team based approach to patient care	MSF		
	ing education and training for junior colleagues and other ers of the healthcare team			
	g with deteriorating performance of colleague (e.g. fatigue)			
 Delive 	ring high quality care			
Leads and par	ticipates in multi disciplinary team meetings	CbD, mini-CEX	3	
Delegates app experienced co	ropriately whilst providing appropriate supervision to less olleagues	CbD, MSF	3	
Behaviours				
	n open environment to foster and explores concerns and the functioning and safety of team working	CbD, MSF	3	
Recognises lin within these	nits of own professional competence and only practise	CbD, MSF	3	
Demonstrates	assertiveness when appropriate	CbD, MSF	3	
Recognises ar	d respects the request for a second opinion	CbD, MSF	3	
Recognises the	e importance of induction for new members of a team	CbD, MSF	3	
	e importance of prompt and accurate information sharing disciplinary and Primary Care teams following hospital	CbD, mini-CEX , MSF	3	
Level descrip	tors			
	Develops the leadership skills necessary to lead teams s and able to deliver better safer care	o that they are more ef	fective	
Intermediate	Comprehends need for optimal team dynamics and prom	notes conflict resolution		
	Demonstrates ability to convey to patients after a handov a different team, the care is continuous	er of care that although	there is	
	Leads multi-disciplinary team meetings allowing all voice	s to be heard and cons	idered	
	Fosters an atmosphere of collaboration			
Advanced	Comprehends situations in which others are better equipped to lead or where delegation is appropriate			
	Ensures that team functioning is maintained at all times Promotes rapid conflict resolution			
 Control of the control of the control				

1.7 Principles of quality and safety improvement

To recognise the desirability of monitoring performance, learning from mistakes and adopting no blame culture in order to ensure high standards of care and optimise patient safety

Knowledge	to ensure high standards of care and optimise patient sa	Assessment	GMP		
Kilowiedge		Methods	GIVIF		
(NCEPOD, IRN	and national significant event reporting systems IER, morbidity and mortality, etc) and how this is dealt cal oncology departments	CbD, mini-CEX	1		
Outlines local hetc)	ealth and safety protocols (fire, radiation protection,	CbD	1		
	sks associated with radiation, chemotherapy and pies and mechanisms to reduce risk	CbD, First Part FRCR	1		
Skills					
Adopts strategi	es to reduce risk	CbD	1,2		
	at governance safeguards high standards of care and evelopment of improved clinical services	CbD	1,2		
Recognise imp effectiveness	ortance of evidence-based practice in relation to clinical	CbD	1		
	rly on own standards of medical practice in accordance ance on licensing and revalidation	CbD	1,2,3, 4		
Behaviours					
Demonstrates a	a willingness to adhere to departmental protocols	CbD, MSF	3		
Develops reflect practice	ction in order to achieve insight into own professional	CbD, MSF	3		
Demonstrates personal commitment to improve own performance in CbD the light of feedback and assessment		CbD	2		
	a willingness to participate in, contribute to, respond toomes of safety and quality improvement strategies,	CbD, Audit Assessment	1,2,3		
	orting adverse clinical incidents and taking part in the sequent investigation in serious incidents				
	lit of personal and departmental and directorate formance				
	ors / discrepancy meetings				
	cal incident and near miss reporting				
	morbidity and mortality meetings				
	al and national databases				
	n open no blame culture	CbD, MSF	3		
Level Descript	Level Descriptor				
	Engages in audit and understands the link between aud improvement	it and quality and saf	fety		
Intermediate	Demonstrates personal and service improvement in per				
	Designs audit protocols and completes audit cycle throu relevant changes needed to improve care and is able to change				

1.8 Complaints and medical error

To recognise the causes of error and to learn from them

To realise the importance of honesty and effective apology

To take a leadership role in the handling of complaints

Knowledge		Assessment Methods	GMP
Describes the	local complaints procedure	CbD, MSF	1
Recognises fa	actors likely to lead to complaints (poor communication, inical errors, adverse clinical outcomes etc)	CbD, MSF	1
Outlines the p	rinciples of an effective apology	CbD, DOPS, MSF	1
	rces of help and support for patients and self when a nade about self or a colleague	CbD, DOPS, MSF	1
Skills			
Contributes to learned from	processes whereby complaints are reviewed and	CbD, MSF	1
	hen something has gone wrong and identifies aff to communicate with	CbD, MSF	1
	opropriate apology and explanation (either of error or for restigation of potential error and reporting of the same)	CbD, MSF	1,3,4
Distinguishes organisationa	between system and individual errors (personal and	CbD, MSF	1
Shows an abi	lity to learn from previous error	CbD, MSF	1
Behaviours			
Adopts behav	riour likely to prevent causes for complaints	CbD, mini-CEX, MSF	1, 3
Deals approp	riately with concerned or dissatisfied patients or relatives	CbD, mini-CEX, MSF	1,3
Acts with hon-	Acts with honesty and sensitivity in a non-confrontational manner CbD, mini-CEX, MSF		
	ne impact of complaints and medical error on staff, the National Health Service	CbD, MSF	1,3
Contributes to errors	a fair and transparent culture around complaints and	CbD, MSF	1
Recognises that complaint	ne rights of patients, family members and carers to make	CbD, MSF	1,4
Recognises the	ne impact of a complaint upon self and seeks appropriate port	CbD, MSF	1,2,4
Level Descri	ptors		
Intermediate	Manages conflict without confrontation		
Comprehends and responds to the difference between system failure and individual error Comprehends and manages the effects of any complaint within members of the team Takes active role in responding to complaints and provides timely accurate written response when required			

1.9 Communication with colleagues and cooperation

To recognise and accept the responsibilities and role of the doctor in relation to other healthcare professionals

To communicate succinctly and effectively with other professionals as appropriate.

Knowledge		Assessment Methods	GMP
Practice" on W The tea	e principles of effective inter-professional collaboration to	CbD, MSF	1
i i	imise patient care principles of confidentiality that provide boundaries to	CbD	1
Outlines techn colleagues	iques to manage anger and aggression in self and	CbD	1
	consibility of the doctor in the management of physical ill health in self and colleagues.	CbD	1
Skills			
	s accurately, clearly, promptly and comprehensively with gues in a timely manner	CbD, mini-CEX	1,3
	Outlines procedures for seeking patient consent for disclosure of C information and situations where consent while desirable is not		1,3
	vioural management skills with colleagues to prevent onflict and enhance collaboration	CbD, mini-CEX, MSF	1,3
Behaviours			
including adop	ness of the importance of multi-disciplinary teamwork, tion of a leadership role when appropriate but also nere others are better equipped to lead	CbD, DORPS, DOST, mini-CEX, MSF	3
	portive and respectful environment where there is open not communication between all team members	CbD, mini-CEX, MSF	1,3
	priate confidentiality is maintained during nember of the team	CbD, mini-CEX, MSF	1,3
Recognises th team	e need for a healthy work/life balance for the whole	CbD, mini-CEX, MSF	1,3
Accepts additional duties in situations of unavoidable and CbD, MSF 1 unpredictable absence of colleagues ensuring that the best interests of the patient are paramount			1
Level Descrip	otors		
Intermediate	Intermediate Fully comprehends the role of and communicates appropriately with all relevant potential team members (individual and corporate)		
Advanced	Takes a leadership role as appropriate, fully respecting the viewpoints of all team members	ne skills, responsibilities	and

1.10 Medical ethics and confidentiality

To know, understand and apply appropriately the principles, guidance and laws regarding medical ethics and confidentiality

ethics and con	ndentiality		
Knowledge		Assessment Methods	GMP
Outlines and fo confidentiality	ollows the guidance given by the GMC on	CbD, mini-CEX	1
Defines the pri	nciples of Information Governance	CbD, mini-CEX	1
Skills			
	es information with the highest regard for and encourages such behaviour in other members	CbD, mini-CEX, MSF	1,2,3
Recognise the without patient	problems posed by disclosure in the public interest, is consent	CbD, mini-CEX, MSF	1,4
	notes strategies to ensure confidentiality is . anonymisation	CbD	1
	nts on the need for information distribution within e immediate healthcare team	CbD, MSF	1, 3
effectively whe	nts, family, carers and advocates tactfully and n making decisions about resuscitation status, and withdrawing treatment	CbD, mini-CEX, Patient Survey	1,3
Behaviours			
Encourages inf	formed ethical reflection in others	CbD, MSF	1
	ess to seek advice of peers, legal bodies and the ere are ethical dilemmas regarding confidentiality a sharing	CbD, mini-CEX, MSF	1
Respects patients' requests for information not to be shared, unless this puts the patient, or others, at risk of harm CbD, mini-CEX, 1,4 Patient Survey		1,4	
	ess to share information with patients about their ey have expressed a wish not to receive such	CbD, mini-CEX	1,3
Level descript	tor		
Intermediate Considers the need for ethical approval when patient information is to be used for anything other than the individual's care. Differentiates between confidentiality and anonymity			

1.11 Medical ethics and conflict of duty

To know, understand and apply appropriately the principles and guidance regarding conflicts between different ethical duties

	Assessment Methods	GMP
Discusses the conflict between ethical duties both to the individual and between the individual patient and broader notions of justice		1,3,4
y of decision making where conflicting duties a decision on ethical grounds	CbD, Final FRCR	1,4
Explains to patients and their relatives concerns about treatments that are not normally funded		3,4
Recognise the factors influencing ethical decision making, including religion, personal and moral beliefs, cultural practices		1,4
Shows willingness to seek the opinion of others when making decisions about ethical issues		1,3
Respects opinions of others, including patients, when making decisions about ethical issues		3,4
conflicting issues to deliver optimal patient ca	re	
	y of decision making where conflicting duties a decision on ethical grounds neir relatives concerns about treatments that uencing ethical decision making, including ral beliefs, cultural practices the opinion of others when making sues ars, including patients, when making sues	ween ethical duties both to the individual and tient and broader notions of justice The opinion of others when making the opinion of others when making to the opinion of others when the op

1.12 Medical ethics and autonomy and capacity

To know, understand and apply appropriately the principles and guidance regarding the concepts of autonomy and capacity.

Knowledge	Assessment Methods	GMP
Discusses the value and limitations of promotion of autonomy in medicine.	CbD, Final FRCR	1,4
Describes the components necessary for informed consent	CbD, Final FRCR	1,3.4
Describes the tests for Assessing Capacity	CbD, Final FRCR	1,3,4
Accepts the need to respect competent refusal	CbD, Final FRCR	1,3,4
Discusses the principles and implications of the Mental Capacity Act, advanced refusals, enduring power of attorney, independent mental capacity advocates	CbD, mini-CEX Final FRCR	1
Skills		
Communicates honestly with patients and their relatives about their disease, benefits and side-effects of treatment and their prognosis	CbD, Final FRCR	3,4
Negotiates with relatives to avoid collusion with them to deny the patient information about their illness	CbD, Final FRCR	3,4
Assesses capacity and understands the legal and moral implications of its presence and absence.	CbD, Final FRCR	3,4
Behaviours		
Treats patients with respect and without discrimination, is polite, considerate and honest, and shows respect for dignity and privacy.	CbD, mini-CEX, MSF	3,4
Treats patients fairly and as individuals	CbD, mini-CEX, MSF	3,4
Level descriptor		
Intermediate Shows ability to support decision making on behalf of decisions about their own care	f those not competent to	make

1.13 Medical ethics and end of life issues

To understand the ethical and legal issues at the end of life and the concepts of acts, omissions and double effect.

Knowledge	Assessment Methods	GMP
Defines the standards of practice defined by the GMC when deciding to withhold or withdraw life-prolonging treatment	CbD, mini-CEX	1
Appreciates that both acts and omissions carry moral and legal culpability but that whilst allowing patients to die may be defensible, killing them is not.	CbD, Final FRCR	1
Accepts that omissions are not legitimate where there is a clear duty to act	CbD, Final FRCR	1
Defines the doctrine of double effect	CBD, Final FRCR	1
Discusses the current guidance on DNAR orders and controversies about these	CBD, Final FRCR	1
Discusses the arguments for and against euthanasia and describes the legal position	CBD, Final FRCR	1
Identifies sources of advice for complex ethical/legal issues	CBD, Final FRCR	1
Skills		
Applies clear and logical thinking around legal and ethical issues at the end of life	CBD, Final FRCR	1
Documents the issues and views that have been considered, the decisions reached and the reasoning behind those decisions in complex end of life decisions.	CBD, Final FRCR	1,3
Seeks, listens to and values other people's opinions in complex end of CBD, Final FR life decisions		1,3
Behaviours		
Show willingness to seek the opinion of others when making decisions about resuscitation status, and withholding or withdrawing treatment	CbD, mini-CEX, MSF	1, 3
Values consensus in complex end-of-life decision making	CBD, Final FRCR	1,3
Level descriptor		
Intermediate Supports the decision making around end of life issues, including those who are no competent to make decisions about their own care.		

1.14 Valid consent

To obtain valid	consent from the patient		
Knowledge		Assessment Methods	GMP
Outlines the GI	MC guidance on consent	CbD, DOST, MSF	1
Skills			
Gives the patie to make an info	nt and his/her carers the information and time required ormed decision	CbD, DOST, mini- CEX, Patient Survey	1,3
Provides a bala	anced honest view of treatment options	CbD, DOST, mini- CEX, Patient Survey	1,3,4
Behaviours			
Respects the p	atient's rights to autonomy	CbD, DOST, mini- CEX, Patient Survey	1,3,4
Shows willingn where appropri	ess to seek advice or offer the patient a second opinion ate	CbD, mini-CEX, MSF	1,3,4
Only obtains consent for procedures which they are not competent to perform, in accordance with GMC/regulatory guidance		1, 3	
Level Descrip	tor		
Intermediate	Supports patients in decision making and obtains valid competent to make decisions about their own care	consent, including those	not

1.15 Legal framework for practice

To understand the legal framework within which healthcare is provided in the UK and/or devolved administrations in order to ensure that personal clinical practice is always provided in line with this legal framework

Knowledge	Assessment Methods	GMP
Illustrates that all decisions and actions must be in the best interests of the patient	CbD, mini-CEX	1
Describes the legislative framework within which healthcare is provided in the UK and/or devolved administrations, including:	CbD, mini-CEX	1, 2
 death certification and the role of the Coroner/Procurator Fiscal 		
child protection legislation		
 mental health legislation (including powers to detain a patient and giving emergency treatment against a patient's will under common law); 		
 advanced directives and living Wills 		
 withdrawing and withholding treatment 		
 decisions regarding resuscitation of patients 		
medical risk and driving		
Data Protection and Freedom of Information Acts		
• IRMER		
Outlines sources of medical legal information	CbD, mini-CEX	1
Describes disciplinary processes in relation to medical malpractice	CbD, mini-CEX, MSF	1
Outlines the role the medical practitioner in relation to personal health and substance misuse, including understanding the procedure to be followed when such abuse is suspected.	CbD, mini-CEX, MSF	1
Skills		
Cooperates with other agencies with regard to legal requirements	CbD, mini-CEX	1, 3
Prepares appropriate medical legal statements for submission to the Coroner's Court, Procurator Fiscal and other legal proceedings and is prepared to present such material in court	CbD, MSF	1
Practices and promotes accurate documentation within clinical practice	CbD, mini-CEX	1, 3
Behaviour		
Show willingness to seek advice from the employer, appropriate legal bodies (including defence societies), and the GMC on medico-legal matters	CbD, mini-CEX, MSF	1
Incorporates legal principles into day to day practice	CbD, mini-CEX	1
Demonstrates that all decisions and actions must be in the best interests of the patient	CbD, mini-CEX, MSF	1, 3

Level Descrip	tors
	Actively promotes discussion on medical legal aspects of cases within the clinical environment.
Intermediate	Participates in decision making with regard to resuscitation decisions and around decisions related to driving discussing the issues openly but sensitively with patients and relatives
Advanced	Works with external strategy bodies around cases that should be reported to them, collaborating with them on complex cases providing full medical legal statements as required and present material in Court where necessary
Auvanceu	Leads the clinical team in ensuring that medico- legal factors are considered openly and consistently wherever appropriate in the care and best interests of the patient, ensuring that patients and relatives are involved openly in all such decisions.

1.16 Ethical research

To ensure that research is undertaken using relevant ethical guidelines		
Knowledge	Assessment Methods	GMP
Outlines the GMC guidance on good practice in research	CbD	1
Describes the components of GCP	CbD	1
Describes the background behind ethical codes for scientific research (Nuremberg, Helsinki etc)	CbD	1
Defines the difference between audit and research	CbD, Audit assessment	1
Demonstrates a knowledge of research principles	CbD, First FRCR	1
Outlines the principles of formulating a research question and designing a project	CbD, mini-CEX	1
Comprehends principal qualitative, quantitative, bio-statistical and epidemiological research methods	CbD, First FRCR	1
Describes the mechanism of ethical approval for research studies	CbD	
Outlines sources of research funding	CbD	1
Discusses the ethical rationale and values the importance of scientific research	CbD	1
Discusses the potential for conflicting ethical values between patient care and scientific research and how these are resolved	CbD	1
Skills		
Skills Uses critical appraisal skills and applies these when reading literature	CbD, First FCR	1
	CbD, First FCR	1
Uses critical appraisal skills and applies these when reading literature		·
Uses critical appraisal skills and applies these when reading literature Demonstrates the ability to write a scientific paper	CbD	1
Uses critical appraisal skills and applies these when reading literature Demonstrates the ability to write a scientific paper Applies for appropriate ethical research approval Understands the difference between population-based assessment and unit-based studies and be able to evaluate outcomes for	CbD CbD	1
Uses critical appraisal skills and applies these when reading literature Demonstrates the ability to write a scientific paper Applies for appropriate ethical research approval Understands the difference between population-based assessment and unit-based studies and be able to evaluate outcomes for epidemiological work Assesses research against the criteria to determine whether it is ethical, including: • Social/ Scientific value	CbD CbD, First FCR	1 1 1
Uses critical appraisal skills and applies these when reading literature Demonstrates the ability to write a scientific paper Applies for appropriate ethical research approval Understands the difference between population-based assessment and unit-based studies and be able to evaluate outcomes for epidemiological work Assesses research against the criteria to determine whether it is ethical, including: • Social/ Scientific value • Scientific validity	CbD CbD, First FCR	1 1 1
Uses critical appraisal skills and applies these when reading literature Demonstrates the ability to write a scientific paper Applies for appropriate ethical research approval Understands the difference between population-based assessment and unit-based studies and be able to evaluate outcomes for epidemiological work Assesses research against the criteria to determine whether it is ethical, including: Social/ Scientific value Scientific validity Fair subject selection	CbD CbD, First FCR	1 1 1
Uses critical appraisal skills and applies these when reading literature Demonstrates the ability to write a scientific paper Applies for appropriate ethical research approval Understands the difference between population-based assessment and unit-based studies and be able to evaluate outcomes for epidemiological work Assesses research against the criteria to determine whether it is ethical, including: • Social/ Scientific value • Scientific validity • Fair subject selection • Favourable risk/ benefit ratio	CbD CbD, First FCR	1 1 1
Uses critical appraisal skills and applies these when reading literature Demonstrates the ability to write a scientific paper Applies for appropriate ethical research approval Understands the difference between population-based assessment and unit-based studies and be able to evaluate outcomes for epidemiological work Assesses research against the criteria to determine whether it is ethical, including: • Social/ Scientific value • Scientific validity • Fair subject selection • Favourable risk/ benefit ratio • Independent review	CbD CbD, First FCR	1 1 1
Uses critical appraisal skills and applies these when reading literature Demonstrates the ability to write a scientific paper Applies for appropriate ethical research approval Understands the difference between population-based assessment and unit-based studies and be able to evaluate outcomes for epidemiological work Assesses research against the criteria to determine whether it is ethical, including: Social/ Scientific value Scientific validity Fair subject selection Favourable risk/ benefit ratio Independent review Informed consent	CbD CbD, First FCR	1 1 1
Uses critical appraisal skills and applies these when reading literature Demonstrates the ability to write a scientific paper Applies for appropriate ethical research approval Understands the difference between population-based assessment and unit-based studies and be able to evaluate outcomes for epidemiological work Assesses research against the criteria to determine whether it is ethical, including:	CbD CbD, First FCR	1 1 1
Uses critical appraisal skills and applies these when reading literature Demonstrates the ability to write a scientific paper Applies for appropriate ethical research approval Understands the difference between population-based assessment and unit-based studies and be able to evaluate outcomes for epidemiological work Assesses research against the criteria to determine whether it is ethical, including: Social/ Scientific value Scientific validity Fair subject selection Favourable risk/ benefit ratio Independent review Informed consent	CbD CbD, First FCR	1 1 1

Level Descri	ptors
Intermediate	Demonstrates critical appraisal skills and demonstrates ability to critically appraise a published paper Demonstrates knowledge of research organisation and funding sources
Advanced	Demonstrates ability to write a scientific paper Demonstrates ability to apply for appropriate ethical research approval if appropriate Provides leadership in research when relevant Promotes research activity

1.17 Evidence and guidelines

To make the optimal use of current best evidence in making decisions about the care of patients To develop the ability to construct evidence based guidelines and protocols in relation to medical practise

Knowledge		Assessment Methods	GMP
Outlines the pri	inciples of critical appraisal	CbD, First FRCR	1
Describes the	advantages and disadvantages of different study (quantitative and qualitative) for different types of	CbD, First FRCR	1
Outlines levels	of evidence and quality of evidence	CbD, First FRCR	1
Demonstrates	how to apply statistics in scientific medical practice	CbD, First FRCR	1
	between the use and differences between the basic sk and uncertainty	CbD, First FRCR	1
	role and limitations of evidence in the development of es and protocols	CbD, First FRCR	1
Describes how SIGN)	guidelines and protocols are developed (e.g. NICE and	CbD	1
Skills			
	nedical literature including use of PubMed, Medline, ews and the internet	CbD	1
Appraises retri	eved evidence to address a clinical question	CbD	1
Applies conclu	sions from critical appraisal into patient care	CbD	1
	the construction, review and updating of local (and lines of good practice	CbD	1
Behaviours			
	linical practice (clinical effectiveness) at all times, as idence based medicine	CbD, mini-CEX	1
Recognises kn	owledge gaps and seeks to address them	CbD, MSF	1
	te with national reviews, key new relevant research, of practice (e.g. NICE and SIGN)	CbD	1
Recognises the	e need to practise outside clinical guidelines at times	CbD, mini-CEX	1
	information about risk and risk-benefit trade-offs, in the individual patient	CbD, mini-CEX	1,3,4
Encourages dis practice	scussion amongst colleagues on evidence-based	CbD, mini-CEX, MSF	1
Level Descripto	ors		
Undertakes a literature review in relation to a clinical problem or topic and present the same Explains the evidence base of clinical care to patients and to other members of the			
Advanced	clinical team Produces a review on a clinical topic, having reviewed and appraised the relevant literature		ant
Advanced	Collaborates in a systematic review of the medical litera		·
	Contributes to the development of local or national clinical guidelines and protocols		

1.18 Audit

Discusses the na	rence between audit and research	Assessment Methods Audit assessment	GMP
Discusses the na	rence between audit and research	Audit assessment	
		tool, CbD	1
the addit cycle ar	ature of the audit cycle, including the steps involved in and its role in improving patient care and services	Audit assessment tool	1
Identifies approp	riate data collection, statistical and analytical methods g practice	Audit assessment tool	1
Discusses chang resistance to cha	e management and the importance of reducing inge	Audit assessment tool, CbD	1
	orking and use of national and local databases for registries, cancer minimum dataset, cancer waiting	Audit Assessment tool, CbD	1
Skills			
Designs, impleme	ents and completes audit cycles, including:	Audit assessment	1,2
 Identifyin 	ng an appropriate subject for audit	tool	
 Identifyin 	ng suitable guidelines to audit against		
 Designin 	g a form for collection of relevant data		
guideline	ing the data extracted and comparing this with the es and reaching conclusions using appropriate I and analysis methods		
 Developi 	ng an action plan		
 Presentir an audit 	ng the data, conclusions and possible action plan to meeting		
 Identifyin 	ng the change in outcomes required		
 Identifyin outcome 	ng the change in processes required to achieve those s		
Negotiati changes	ing with the individuals who can deliver those		
Contributes to loc NCEPOD	cal and national audit projects appropriately, e.g.	Audit assessment tool, CbD	1,2
Supports audit w	ithin the MDT	Audit assessment tool, CbD	1,2
Behaviours			
Recognise the ne setting and qualit	eed for audit in clinical practice to promote standard by assurance	Audit Assessment tool, CbD	1, 2
Shows willingnes audits	ss to support changes identified as necessary by	Audit Assessment tool, CbD	1,2
Level Descripto	rs		
Organises or leads a departmental audit Compares the results of an audit with criteria and standards to reach conclusions Uses the findings of an audit to develop and implement change Understands the links between audit and quality improvement			ons
Advanced r	Leads a complete clinical audit cycle including development of conclusions, the change needed for improvement, implementation of findings and re-audit to assess the effectiveness of the change Organises or leads a departmental audit meeting		

1.19 Continuing professional development

To be able to ta	ake responsibility for personal learning and continuing pr	ofessional developm	nent.
Knowledge		Assessment Methods	GMP
Describes how development	adults learn and how principles relate to personal	CbD	1
Outlines the str	ructure of an effective appraisal interview	CbD	1
Differentiates b	etween appraisal and assessment and performance	CbD	1
Discusses who	to refer to if problems are identified during training	CbD	1
Skills			
	onal development plan and portfolio to ensure conal development	MSF	1
Uses workplace for personal de	e-based assessments and appraisals as an opportunity velopment	CbD, MSF	1
Uses different land knowledge	earning methods effectively to develop personal skills	MSF	1
Behaviours			
Shows willingn	ess to seek and learn from feedback	MSF	1,3
Show willingne	ss to undertake workplace-based assessments	CbD, MSF	1
	scussions colleagues with colleagues to share I understanding	CbD, MSF	1,3
Maintains hone	esty and objectivity during appraisal and assessment	CbD, MSF	1
Recognises the professional be	e importance of personal development in guiding good shaviour	CbD, MSF	1
Demonstrates through continu	a willingness to advance own educational capability uous learning	CbD, MSF	1
	loro		
Level Descrip	lors		

1.20 Teaching

To be able to deliver teaching in a variety settings		
Knowledge	Assessment Methods	GMP
Describes how adults learning principles relate to medical education	CbD, Teaching observation	1
Demonstrates knowledge of relevant developments and challenges in medical education	CbD, Teaching observation	1
Describes the assessment system and its place in relation to formative and summative assessment	CbD, Teaching observation	1
Demonstrates an understanding of the place of workplace based assessments	CbD, Teaching observation	1
Skills		
Identifies learning needs of others and self and varies teaching format appropriately	CbD, MSF, Teaching observation	1
Structures and delivers clinical teaching sessions effectively, including:	MSF, Teaching observation	1
Small group teaching		
 Presentations 		
• Lectures		
Bed side teaching sessions		
Appropriate design and use of audiovisual aidsAllowing active audience participation		
Communicates feedback effectively and appropriately	MSF	1
Undertakes supervision, workplace-based assessments, appraisal, mentoring as appropriate	MSF	1
Recognises the trainee in difficulty and take appropriate action, including where relevant referral to other services	CbD, MSF	1
Leads departmental teaching programmes including journal clubs	CbD, Teaching observation	1
Participates in strategies aimed at improving patient education, e.g. talking at support group meetings	CbD, MSF	1

Behaviours			
Maintains digni educational du	ty and safety of patients at all times when discharging ties	CbD, MSF, Teaching observation	1,4
Shows willingn	ess to seek and learn from feedback	MSF, Teaching observation	1,3
social workers in a variety of settings		CbD, MSF, Teaching observation	1
Demonstrates consideration for learners, including their emotional, physical and psychological well being with their development needs.		CbD, MSF, Teaching observation	1
Acts to ensure equality of opportunity for students, trainees, staff and professional colleagues		CbD, MSF, Teaching observation	1
Shows willingness to undertake assessment of workplace-based assessments		CbD, MSF	1
Maintains hone	esty and objectivity during appraisal and assessment	CbD, MSF	1
Recognises the importance of personal development in guiding CbD, MSF trainees in aspects of good professional behaviour		1	
Level Descrip	tors		
Intermediate	Delivers teaching to different staff groups in a variety of formats Performs workplace-based assessments, giving effective and appropriate feedback Acts as a mentor for junior colleagues		
Advanced	Plans and organises a teaching programme within the o	oncology department	

1.21 Management and NHS structure

To understand the structure of the NHS and the management of local healthcare systems in order to be able to participate fully in managing healthcare provision

Knowledge	Assessment Methods	GMP
Outlines the guidance given on management and doctors by the GMC	CbD	1
Describes the function and responsibilities of National bodies, such as the Department of Health, Scottish Government, SHAs, PCTs, NICE, GMC	CbD	1
Evaluates major national reports on cancer care e.g. Cancer Reform Strategy, National Radiotherapy Advisory Group and National Chemotherapy Advisory Group reports	CbD	1
Evaluates possible future developments in the organisation of cancer services	CbD	1
Describes the local structure of NHS systems in the locality, including the department's management and committee structure recognising the potential differences between the four countries of the UK	CbD	1
Describes how cancer services are commissioned for patients	CbD	1
Understands the consistent debates and changes that occur in the NHS including the political, social, technical, economic, organisational and professional aspects that can impact on provision of service	CbD	1
Describes the principles of:	CbD, mini-CEX	1
Clinical coding		
European Working Time Regulations including rest provisions		
NHS finance and budgeting		
 Consultant contract and the contracting process Resource allocation 		
The role of the independent sector as providers of healthcare		
Patient and public involvement processes and role		
Recruitment and appointment procedures		
Skills		
Participates in managerial meetings	MSF, CbD	1
Works with stakeholders to create and sustain a patient-centred service	CbD, mini-CEX	1
Analises information and uses it appropriately to promote service developments	CbD, mini-CEX	1
Prioritises use of resources, including allocating beds and making best use of staffing resources, particularly when these are stretched by competing demands	MSF	

Behaviour			
	e importance of equitable allocation of healthcare of commissioning	CbD	1,2
Recognises th systems	e role of doctors as active participants in healthcare	CbD, mini-CEX	1,2
	ropriately to health service objectives and targets and edevelopment of services	CbD, mini-CEX	1,2
•	e role of patients and carers as active participants in tems and service planning	CbD, mini-CEX, Patient Survey	1,2,3
Takes an activ	e role in promoting the best use of healthcare resources	CbD, mini-CEX, MSF	1
management of	ness to improve leadership and managerial skills (e.g. courses) and engage in leadership and management of g. to be a member of departmental and cancer network	CbD, MSF	1
Level Descript	ors		
Discusses guidance from the relevant health regulatory agencies in relation to cancer care Intermediate Describes the local structure for health services and how they relate to regional or devolved administration structures			
Discusses funding allocation processes from central government in outline and how that might impact on the local health organisation Participates fully in clinical directorate meetings and other appropriate local management structures in planning and delivering healthcare within oncology Collaborates with other stake holders in the cancer community to ensure that their needs and views are considered in managing services Participates as appropriate in staff recruitment processes			

2 Introductory module

2.1 Authorising chemotherapy

To be able to review a patient receiving cytotoxic chemotherapy

To authorise the next cycle of previously-prescribed treatment, enabling treatment to proceed.

To dutilonise the next dyole of previously presented treatment, chabing treatment to proceed.			
Knowledge	Assessment Methods	GMP	
Describes safe handling of cytotoxic drugs	CbD	1,2	
Describes the methods of calculating the correct dose of chemotherapy	CbD	1	
Describes the possible side effects of treatment	CbD	1	
Skills			
Takes a focused history to ensure that patient's condition has not changed since treatment was prescribed	DOST	1,3	
Identifies when the dose should be reduced or the cycle delayed	CbD, DOST	1,2	
Behaviour			
Elicits patient and carers concerns about treatment and ensures that they are addressed appropriately	DOST, MSF	3,4	
Ensures that patient has all relevant written information regarding treatment, especially emergency contact instructions	DOST, MSF	2,3,4	
Remains open to advice from other health professionals on chemotherapy issues	DOST, MSF	1,3	
See sections 1.3, 1.4 and 1.5	DOST, MSF	3,4	

2.2 Prescribing chemotherapy

To be able to prescribe cytotoxic chemotherapy within local guidelines, continuing a planned course of treatment (but not initiate first cycle of treatment).

Knowledge	Assessment Methods	GMP
Describes the common side effects of chemotherapy in common use	CbD, DOST	1,2
Describes the use of supportive measures both pharmacological and non pharmacological to treat toxic effects of chemotherapy	CbD, DOST	1,2
Describes methods of assessing tumour response	CbD, DOST	1
Defines the effects of age, body size, organ dysfunction and concurrent illnesses on drug distribution and metabolism of cytotoxic drugs	CbD, DOST	1,2
Skills		
Takes a focused history and performs a relevant examination to assess tumour response, side effects of treatment, patient's performance status and co-morbidities	DOST	1,2,3
Assesses toxicity of the previous cycle of chemotherapy	DOST	1,2
Modifies the dose of chemotherapy correctly in response to clinical findings and laboratory parameters	DOST	1,2
Ensures appropriate arrangements are in place for subsequent patient review	CbD, DOST	1
Uses electronic prescribing system where available to improve patient safety	DOST	1,2
Behaviour		
Ensures treatment information is shared promptly and accurately with patient's GP and other specialties involved in supporting the patient	CbD, DOST	1,3
See sections 2.1, 1.3, 1.4 and 1.5		

2.3 Safety in radiation treatment

To be aware of issues of patient and personal safety with regard to radiation treatment.			
Knowledge	Assessment Methods	GMP	
Describes IRMER regulations and the procedures in place in the department to comply with these	CbD	1,2	
Identifies the requirement for an ARSAC certificate	CbD	1,2	
Skills			
See Section 1.5			
Behaviour			
See Section 1.5	·		

2.4 Outpatient consultation

To be able to structure an outpatient consultation and to communicate with patients clearly and in an empathetic manner.

Knowledge	Assessment Methods	GMP
Recognises that patients do not present a history in a structured fashion	mini-CEX,	1,3
Recognises that patient's wishes and beliefs and the history should inform examination and investigations	mini-CEX	1
Discusses the need for targeted clinical examination	CbD, mini-CEX	1
Discusses the limitations of physical examination and the need for appropriate investigations to confirm a diagnosis	CbD, mini-CEX	1
Skills		
Assesses and summarises the previous hospital notes	CbD, mini-CEX	1
Greets patient appropriately and establishes a rapport, overcoming barriers to communication	mini-CEX	1,3
Elicits patient's main concerns	mini-CEX	1,3,4
Performs focused history and examination	CbD, mini-CEX	1,3
Determines the level of information the patient wishes to receive	mini-CEX	1,3,4
Explains the current situation to the patient and if necessary breaks bad news	mini-CEX	1,3,4
Negotiates agreed outcomes with the patient	mini-CEX	1,3,4
Organises appropriate investigations, treatment and referrals to other professionals	CbD, mini-CEX	1,3
Communicates clearly in the notes and in the letter to the referring doctor and GP	mini-CEX, MSF	3,4
Behaviours		
Treats patients with respect and without discrimination, is polite, considerate and honest, shows respect for dignity and privacy.	mini-CEX, MSF, Patient survey	1,3,4
Treats patients fairly and as individuals	mini-CEX, MSF	1,3,4
Shows empathy with the patient's situation and offers appropriate emotional support	mini-CEX, MSF, Patient survey	3,4
Ensures appropriate personal language and behaviour	mini-CEX, MSF, Patient survey	1,3
Shows willingness to provide the patient with a second opinion	mini-CEX, MSF	1,3
Uses different methods of ethical reasoning to come to a balanced decision where complex and conflicting issues are involved	CbD, mini-CEX, MSF	1,3
Behaves in accordance with Good Medical Practice	mini-CEX, MSF	3,4

2.5 Breaking bad news

To be able to skilfully deliver bad news using appropriate stategies according to the needs of the patients.

Knowledge	Assessment Methods	GMP
Describes models of breaking bad news	CbD, mini-CEX,	1,3
Discusses the range of likely reactions to bad news	CbD, mini-CEX	1,3
Discusses the different connotations of bad news depending on the context, individual, social and cultural circumstances	CbD, mini-CEX	1
Skills		
Recognises the impact of bad news on the patient, carers, staff members and self	CbD, mini-CEX	1,3
Structures interview appropriately and ensures that patient has the necessary support during the interview	CbD, mini-CEX	1,3
Responds to verbal and non-verbal cues from patient and carers	CbD, mini-CEX	1,3
Elicits patient's main concerns	mini-CEX	1,3,4
Determines the level of information the patient wishes to receive	mini-CEX	1,3,4
Explains situation to the patient and carers using appropriate language	CbD, mini-CEX	1,3,4
Encourages questioning and ensures patient understands information given	CbD, mini-CEX	1,3
Ensures that appropriate on going support and follow up arrangements are in place	CbD, mini-CEX, MSF	1,3,4
Behaviours		
Respects the different ways that patients react to bad news	CbD, MSF	1
Shows empathy with the patient's situation and offers appropriate emotional support	mini-CEX, MSF	3,4
Shows respect for the opinions of other team members regarding a patient's likely and on going response to bad news	CbD, MSF	1,3
Encourages team working to ensure that patients receiving bad news have appropriate support	CbD, MSF	1,3

3 Oncology emergencies syllabus

To be completed by the end of ST3

3.1 Infections

To be able to diagnose and manage infections, especially in immunocompromised patients.			
Knowledge	Assessment Methods	GMP	
Lists the infections that occur commonly in cancer patients undergoing treatment and describes how to diagnose them	CbD	1,2	
Knows the antibiotic, antiviral and antifungal policies of the hospital	CbD	1,2	
Skills			
Takes a focused history and performs a focused examination	CbD, mini-CEX	1,2,3,4	
Requests appropriate investigations and interprets X-ray and CT imaging	CbD	1	
Resuscitates patients and prescribes appropriate supportive care and antibiotics	CbD, mini-CEX	1,2	
Evaluates the importance of prognosis in influencing escalation of treatment	CbD	1,2	
Recognises when escalation of care to HDU/ITU is indicated and appropriate	CbD	1,2	
Discusses treatment with patient and carers	mini-CEX	3,4	
Behaviours			
See Sections 1.2, 1.3, 1.4 1.5 and 1.15			

3.2 Spinal cord compression

To be able to diagnose and manage spinal cord compression.			
Knowledge	Assessment Methods	GMP	
Describes the symptoms and signs of spinal cord compression	CbD,	1,2	
Identifies the appropriate radiological investigations	CbD	1,2	
Describes the roles of steroids, surgery, radiotherapy and rehabilitation	CbD	1,2	
Skills			
Assesses the level of spinal cord compression clinically	mini-CEX	1	
Interprets MRI imaging	CbD, DORPS	1	
Discusses options with patient and colleagues and recommends most appropriate management	CbD, mini-CEX	1,3,4	
Plans and prescribes radiotherapy treatment	DORPS	1,2	
Plans appropriate supportive care/rehabilitation	CbD	1,3	
Behaviours			
See Sections 1.2, 1.3, 1.4 and 1.6			

3.3 Superior vena cava obstruction (SVCO)

To be able to diagnose and manage SVCO.			
Knowledge	Assessment Methods	GMP	
Describes the symptoms and signs of SVCO	CbD	1	
Lists the differential diagnosis	CbD	1	
Describes the role of different treatment modalities	CbD	1	
Skills			
Performs a focussed history and examination and recognises the diagnosis clinically	CbD, mini-CEX	1,3,4	
Interprets X-ray and CT imaging	CbD	1,2	
Discusses diagnostic and treatment options with patient and colleagues and recommends the most appropriate pathway	mini-CEX	3,4	
Plans and prescribes radiotherapy/chemotherapy treatment	DORPS, DOST	1,2	
Behaviours			
See Sections 1.3 and 1.4			

3.4 Metabolic disorders

To be able to diagnose and manage metabolic disorders commonly associated with cancer, including hypercalcaemia, hyperuricaemia, tumour lysis syndrome, hypo/hyperglycaemia and hyperbilirubinaemia

Knowledge	Assessment Methods	GMP
Describes the symptoms, signs and laboratory findings of metabolic disorders associated with cancer	CbD	1
Lists the differential diagnosis of the possible causes	CbD	1
Describes measures to reduce the risk of occurrence where appropriate	CbD	1,2
Skills		
Determines the blood tests and imaging studies required to establish a diagnosis and interprets them	CbD	1
Determines and institutes a clinical management and liaises with other specialities as appropriate	CbD	1,2,3
Behaviours		
See Sections 1.3, 1.4 and 1.6		

3.5 Organ failure

To be able to manage major organ failure: respiratory/cardiovascular failure, renal failure and hepatic failure.

Knowledge	Assessment Methods	GMP
Describes the symptoms, signs, laboratory and imaging findings	CbD	1
Lists the differential diagnosis of the possible causes	CbD	1
Skills		
Performs a focused history and examination and is able to develop a differential diagnosis clinically	CbD, mini-CEX	1,3,4
Determines the blood tests and imaging studies required and interprets them	CbD, mini-CEX	1
Evaluates the treatment options and how the patient's prognosis influences these	CbD, mini-CEX	1
Determines and institutes clinical management and liaises with other specialities as appropriate	CbD, mini-CEX	1,2,3
Behaviours		
See Sections 1.2, 1.3, 1.4, 1.6, 1.9, 1.13 and 1.15		

3.6 Reduced conscious level

To be able to manage patients with a reduction in their conscious level.			
Knowledge	Assessment Methods	GMP	
Lists the differential diagnosis of the causes of reduced conscious level	CbD	1	
Describes the legislation around 'loss of capacity' of a patient to make a decision	CbD	1,2	
Skills			
Performs a focussed clinical examination	CbD, mini-CEX	1,3,4	
Determines the blood tests and imaging studies required and interprets them	CbD	1,2	
Evaluates the treatment options and how the patient's prognosis influences these	CbD	1	
Determines and institutes clinical management and liaises with other specialities as appropriate	CbD, mini-CEX	1,2,3	
Behaviours			
See Sections 1.2, 1.3, 1.4, 1.6, 1.9, 1.10, 1.11, 1.12 and 1.15			

4 Site-specific learning outcomes

Each cancer site is placed in one of four groups:

Group A

The common tumours where the majority of learning outcomes should be achieved by the end of ST4

Group B

A group of tumours where the majority of learning outcomes should be achieved by the end of ST5

Group C

A group of tumours where some learning outcomes should be achieved by the end of ST5 and the majority will be achieved by CCT

Group D

A group of uncommon tumours and specialised techniques where a few learning outcomes should be achieved by ST5 and achieved by mainly CCT

For each group of tumours the stage of training by which the trainee should have achieved the learning outcomes is shown as:

- Core completed by the end of ST4
- Intermediate completed by the end of ST5
- Advanced tumour-site specialisation undertaken post-FRCR and completed CCT

Table showing composition of each group

Group	Site/type or treatment technique	Subsite/subtype
Groups A: common subjects where the majority of learning outcomes achieved by the end of ST4	Breast cancer	
	Lung cancer	Non-small cell
		Small cell
	Lower gastrointestinal cancer	Caecum
		Colon
		Rectum
	Urological cancer	Prostate

Group	Site/type or treatment technique	Subsite/subtype
Group B: where the majority of learning outcomes achieved by the end of ST5	Thoracic cancer	Mesothelioma Thymic tumours Mediastinal germ cell
	Upper gastrointestinal cancer	Oesophagus Stomach Pancreas
	Lower gastrointestinal cancer	Anal canal and anal margin
	Head and neck cancer	Larynx Pharynx Oropharynx Oral cavity Paranasal sinuses Nasopharynx Salivary gland tumours Thyroid Middle ear
	Sarcoma	Soft tissue Gastrointestinal stromal tumours
	Gynaecological cancer	Cervix Body of Uterus Ovary
	Urological cancer	Bladder Kidney Penis Testicular tumours
	Central nervous system tumours	Gliomas Meningiomas Vestibular schwannomas Pituitary adenomas
	Skin cancer	Non-melanoma Melanoma
	Lymphoma/leukaemia/myeloma	Hodgkin lymphoma Non-Hodgkin lymphoma Plasmacytoma/myeloma
	Unknown primary cancer	

Group	Site/type or treatment technique	Subsite/subtype
Group C: where some learning outcomes achieved by the end of	Upper gastrointestinal cancer	Gall bladder and biliary tract Primary liver
ST5	Head and neck cancer	Nasal passages Temporal bone tumours
	Sarcoma	Primary bone tumours Ewing's sarcoma of bone and soft tissue (adult)
	Gynaecological cancer	Fallopian tube Primary peritoneum Vulva and vagina
	Urological cancer	Ureter Urethra
	Central nervous system tumours	Craniopharyngioma Ependymoma Pineal lesions Primitive neuroectodermal tumours Primary cerebral lymphoma Medulloblastoma Skull base tumours
	Skin cancer	Cutaneous lymphoma
Group D: a few learning outcomes achieved by the end of ST5 but they will mainly be achieved by CCT	Paediatric and adolescent oncology including specific paediatric malignancies and specific issues arisingwhen treating paediatric patients who have tumours which are found in adults	Central nervous system tumours Wilms' tumour Neuroblastoma Rhabdomyosarcoma Ewing's sarcoma Lymphoma Leukaemia
	Brachytherapy clinical experience	Gynaecological cancer Prostate cancer Head and neck cancer Other
	Proton and neutron therapy	

Underpinning attitudes and behaviours

The site-specific learning outcomes in this section of the syllabus are underpinned by appropriate attitudes and behaviours which are drawn from Good Medical Practice (GMP). Since many of the learning outcomes for these attitudes and behaviours are already listed in the Common Competencies for Clinical Oncology (Appendix 1, Section 1), they are not repeated here; instead, where appropriate, reference is made to the relevant part of Section 1. In summary, each trainee must:

- 1. Display a willingness to make the care of the patient their first concern
- 2. Appreciate the need to protect and promote the health of patients and the public
- 3. Display a willingness to provide a good standard of practice and care by:
 - Keeping their professional knowledge and skills up to date
 - Recognising and working within the limits of their competence
 - Displaying a willingness to work with colleagues in the ways that best serve patients' interests:
 - Respecting their skills and contributions and treating them fairly
 - Communicating effectively with them
 - Supporting colleagues who have problems with performance, conduct or health while protecting patients from risk of harm
 - Avoiding malicious or unfounded criticisms of colleagues
 - o Demonstrating effective handover procedures when going off duty
- 4. Demonstrate the need to treat patients as individuals and respect their dignity, by
 - Treating patients politely, considerately and honestly
 - Respecting patients' right to confidentiality
- 5. Display a willingness to work in partnership with patients:
 - Listening to patients and responding to their questions, concerns and preferences and keeping them informed about the progress of their care
 - Sharing with patients, in a way they can understand, the information they want or need to know about their condition, its likely progression, and the treatment options available to them, including associated risks and uncertainties
 - Respecting patients' rights to reach decisions about their treatment and care
 - Supporting patients in caring for themselves to improve and maintaining their health
- 6. Display honesty and openness and act with integrity:
 - Acting without delay if they have good reason to believe that they or a colleague may be putting patients at risk
 - Never discriminating unfairly against patients or colleagues
 - Never abusing the patients' trust in him/her or the public's trust in the profession, by always displaying:
 - Honesty and trustworthiness when writing or signing any documents, reports or CVs
 - Honesty and integrity when undertaking research putting the protection of the participants' interests first
 - Honesty in financial dealings with employers and other organisations or individuals.

Underpinning scientific knowledge

The scientific knowledge of radiotherapy physics, tumour biology, radiobiology, clinical pharmacology and medical statistics that underpins clinical oncology training is common to all tumour groups. It is therefore essential that trainees acquire this knowledge by the end of core training (ST5). This knowledge is defined in Appendix 2 and is assessed in the First FRCR examination.

Tumour Site-Specific Learning Outcomes

4.1 Radiology

To be able to relate clinical and radiological anatomy to diagnosis an	d therapy	
Level		
Group A – Core Group B – Intermediate Group C – Intermediate Group D – Advanced		
Knowledge	Assessment Methods	GMP
Describes clinical and radiological anatomy	CbD, DORPS, Final FRCR	1
Skills		
Identifies landmarks, key structures including vessels, lymph nodes on CT and MRI	CbD, DORPS, Final FRCR	1
Interprets X-ray, CT, MRI and PET imaging	CbD, DORPS, Final FRCR	1

4.2 Diagnosis and staging

To be able to diagnose and stage cancer.		
Level		
Group A – Core Group B – Intermediate Group C – Intermediate Group D – Advanced		
Knowledge	Assessment Methods	GMP
Discusses the epidemiology and aetiology of the cancer, including: the general principles of tumour biology the genetics of normal and malignant cells the causation of human cancers the normal and aberrant mechanisms of cell growth control	First FRCR	1
Describes the indications for urgent referral by GP	CbD	1,2
Describes the staging and prognostic indices	CbD, Final FRCR	1
Describes the pathological techniques available and limitations of histology and immunohistochemistry and other specialist techniques, e.g. molecular biological techniques	First FRCR, CbD, Final FRCR	1
Skills		
Performs a focussed history and examination	CbD, mini-CEX	1,3
Recommends appropriate diagnostic and staging investigations	CbD	1,2

Behaviours

See Sections 1.2, 1.3 and 1.4

4.3 Prognosis

4.5 Frogriosis		
To be able to assess prognosis.		
Level		
Group A – Core Group B – Intermediate Group C – Intermediate Group D – Advanced		
Knowledge	Assessment Methods	GMP
Describes factors that influence prognosis	CbD, Final FRCR, First FRCR	1
Skills		
Assesses the effect of performance status, stage, age, comorbidity, histological type and other prognostic factors on outcome	CbD, Final FRCR, First FRCR	1
Behaviours		
See Sections 1.3 and 1.4		

4.4 Genetics

4.4 Genetics		
To be able to assess if there is a significant genetic basis for the can	cer.	
Level		
Group A – Core Group B – Intermediate		
Group C – Intermediate Group D – Advanced		
Knowledge	Assessment Methods	GMP
Describes the principles of cancer genetics	First FRCR	1
Describes the features of the personal and family medical history that indicate a high risk of a genetic basis of the disease	CbD, First FRCR	1
Describes when referral for genetic counselling is appropriate	CbD, Final FRCR	1
Explains how a gene abnormality affects the patient's prognosis	CbD, Final FRCR	1
Recognises the impact that discovery of a genetic abnormality may have on the patient and his/her family	CbD, Final FRCR	1
Skills		
Acquires an accurate family history	CbD, mini-CEX	1,3,4
Discusses the possibility of referral for genetic counselling with the patient	mini-CEX	1,3,4
Explains to the patient how the treatment options may be altered by a genetic abnormality	mini-CEX	1,3,4
Behaviours		
See sections 1.3, 1.4, 1.5 and 1.10	·	
Demonstrates willingness to facilitate patient choice regarding decision to undergo genetic testing	mini-CEX, MSF	3,4

4.5 Discussion of treatment options

4.5 Discussion of treatment options		
To be able to discuss treatment options in the light of understanding	of the prognosis.	
Level		
Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Predicts the effects of treatment on prognosis	CbD, Final FRCR	1
Recognises when radical and when palliative treatments are appropriate	CbD, Final FRCR	1
Skills		
Informs patients of treatment options and discusses individual risk/benefit	CbD, Final FRCR, mini-CEX	1,3,4
Communicates appropriately with a wide variety of patients including:		
working with interpreters to deal with patients from diverse backgrounds	mini-CEX, MSF	3,4
communicating with patients with special educational needs and their carers		
Behaviours		
See sections 1.3, 1.4, 1.5 and 1.11	-	

4.6 Multi-disciplinary team (MDT) meetings

To be able to take part in discussions in tumour-site specific MDT meetings.		
Level		
Group A – Core Group B – Intermediate		
Group C – Advanced Group D – Advanced Knowledge	Assessment Methods	GMP
Describes the indications for treatment and the risks and benefits of different treatment options	CbD, Final FRCR	1,2
Describes the results of major randomised trials that have influenced present practice	CbD, Final FRCR	1
Describes major national guidelines	CbD, Final FRCR	1
Skills		
Assesses potential risks and benefits of treatment options for the individual patient	CbD, Final FRCR	1,2
Discusses treatment options within the MDT meeting	CbD, Final FRCR	1,3
Behaviours		
See sections 1.3, 1.4, 1.6, 1.9, 1.10 and 1.17		

4.7 Evaluating research

4.1 Evaluating reseal	CII		
To be able to evaluate and syr	nthesise research evidence to change	practice.	
Level			
Group A – Advanced	Group B – Advanced		
Group C – Advanced	Group D – Advanced		
Knowledge		Assessment Methods	GMP
Evaluates the published resea	rch evidence	CbD, Final FRCR, Audit assessment	1
Evaluates ongoing trials of bot	h radiotherapy and systemic therapy	CbD, Final FRCR Audit assessment	1
Evaluates the national and inte	ernational guidelines including NICE	CbD, Final FRCR Audit assessment	1
Skills			
Discusses evidence at MDT w	ith regard to specific patients	CbD	1,2,3
Discusses involvement in clinic	cal trials with colleagues	CbB	1,2,3
Revises or develops departme the management of tumour sit	ental, evidence based guidelines for es	CbD, Audit assessment	1,2,3
Formulates plans to introduce department	new treatments and techniques to a	CbD, Audit assessment	1,2,3
Behaviours			
See sections 1.3, 1.7, 1.16, 1.	17, 1.18 and 1.21		

4.8 First line chemotherapy		
To be able to assess patients for first line chemotherapy.		
Level		
Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Describes the mode of action of cytotoxic drugs and the principles of clinical use of systemic therapies	First FRCR	1
Discusses the principles of pharmacokinetics and pharmacodynamics	First FRCR	1
Describes drug protocols	DOST, mini-CEX, CbD, Final FRCR,	1
Evaluates the benefits and toxicity of chemotherapy	First FRCR, DOST, mini-CEX, CbD, Final FRCR, MSF	1,2,4
Decides which regimes are appropriate in the clinical situation	DOST, mini-CEX, CbD, Final FRCR, MSF	1,2,4
Describes tests, procedures or other arrangements required prior to therapy	DOST, mini-CEX, CbD, Final FRCR, MSF	1,2
Skills		
Elicits the patient's wishes with regard to the aims of treatment	DOST, mini-CEX, CbD, MSF	1,2,3,4
Performs an appropriate history & examination	DOST, mini-CEX, Final FRCR,	1,2,4
Assesses performance status and evaluates the information to inform the treatment plan	DOST, mini-CEX, Final FRCR,	1,2,3,4
Behaviours		
See sections 1.3, 1.4 and 1.5		

4.9 Discussing treatment options

To be able to discuss treatment options in the light of understanding of the prognosis.		
Level		
Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Describes the acute and long term risks of chemotherapy	DOST, CbD, mini-CEX, First FRCR, Final FRCR,	1,2,3,4
Describes the aims of treatment and the prognosis	DOST, CbD, mini- CEX, Final FRCR,	1,3,4
Skills		
Explains these issues and the risk/benefit ratio to the patient	mini-CEX, DOST, PS	1,2,3,4
Completes the consent form accurately with the patient	mini-CEX, DOST	1,2,3,4
Behaviours		
See sections 1.3, 1.4, 1.5 and 1.11		

4.10 Initiating chemotherapy

To be able to prescribe the first course of chemotherapy.		
Level		
Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Describes the acute and long term side effects of the chemotherapy	DOST, CbD, First FRCR, Final FRCR,	1,2
Describes the importance of biochemical, haematological and radiological parameters in determining dose of chemotherapy	DOST, CbD, First FRCR, Final FRCR,	1,2
Describes the supportive measures both pharmacological and non- pharmacological to treat toxic effects of chemotherapy	DOST, CbD, First FRCR, Final FRCR,	1,2
Skills		
Generates an appropriate systemic therapy prescription which is safe, accurate and meets local and national standards	DOST, MSF	1,2
Behaviours		
See sections 1.5		

Managing patients receiving chemotherapy To be able to manage patients undergoing radical and palliative chemotherapy treatment regimens. Level Group A – Core Group B – Intermediate Group C – Advanced Group D - Advanced Assessment **GMP** Knowledge **Methods** Describes the physiology of haemopoiesis First FRCR 1 Describes the clinical pharmacology and uses of steroids and anti-First FRCR 1 emetics DOST, CbD, Describes the acute and long term side-effects of chemotherapy 1,2 First FRCR, Final FRCR, DOST, CbD, Describes how to assess tumour response 1 First FRCR, Final FRCR, **Skills** DOST, CbD, Develops a management plan for the patient during the 1,2,3 chemotherapy including the management of side effects Final FRCR DOST, CbD, Prescribes supportive treatments 1,2 Final FRCR DOST, CbD, Judges when to stop or continue treatment 1,2,3,4 Final FRCR, MSF

Behaviours

See sections 1.3, 1.4 and 1.5

4.12 Initiating hormonal therapy

To be able to assess patients for treatment and prescribe hormonal therapy		
Level		
Group A – Core Group B – Intermediate		
Knowledge	Assessment Methods	GMP
Describes common drug protocols	DOST, CbD, Final FRCR	1
Evaluates the benefits and toxicity of treatment	DOST, CbD, First FRCR, Final FRCR	1,2
Decides which regimes are appropriate in the clinical situation	DOST, CbD, Final FRCR	1,2,3
Describes the tests, procedures and other arrangements required prior to and during therapy	DOST, CbD, Final FRCR	1,2
Skills		
Elicit the patient's wishes with regard to the aims of treatment	DOST, mini-CEX, Final FRCR, PS	3
Performs an appropriate history and examination	DOST, mini-CEX, Final FRCR	1,3,4
Assesses performance status		
	DOST, mini-CEX, Final FRCR, CbD	1,3
Generates an appropriate systemic therapy prescription which is safe, accurate and meets local and national standards	DOST, MSF	1,2
Behaviours		
See sections 1.3, 1.4 and 1.5		

4.13 Managing patients receiving hormonal therapy

To be able to manage patients undergoing hormonal therapy		
Level		
Group A – Core Group B – Intermediate		
Knowledge	Assessment Methods	GMP
Describes the acute and long term side-effects of hormonal therapy	DOST, CbD, First FRCR, Final FRCR,	1,2
Describes how to assess tumour response	DOST, CbD, First FRCR, Final FRCR,	1
Skills		
Develops a management plan for the patient during hormonal therapy including the management of side effects	DOST, CbD, Final FRCR	1,2,3
Prescribes supportive treatments	DOST, CbD, Final FRCR	1,2
Judges when to stop or continue treatment	DOST, CbD, Final FRCR, MSF	1,2,3,4
Behaviours		
See sections 1.3, 1.4 and 1.5		

4.14 Assessing patients for biological therapy

To be able to assess patients for treatment with monoclonal antibodies, tyrosine kinase inhibitors, interferons, interleukins.

Group A – Core	Group B – Intermediate
Group C – Advanced	Group D - Advanced

Knowledge	Assessment Methods	GMP
Describes the principles of biological and novel therapies	First FRCR	1
Describes common drug protocols	DOST, CbD, Final FRCR	1
Evaluates the benefits and toxicity of treatment	DOST, CbD, Final FRCR	1,2
Decides which regimes are appropriate in the clinical situation	DOST, CbD, Final FRCR	1,2,3
Describes the tests, procedures and other arrangements required prior to therapy	DOST, CbD, Final FRCR	1,2
Skills		
Elicits the patient's wishes with regard to the aims of treatment	DOST, mini-CEX, Final FRCR, PS	3
Performs an appropriate history and examination	DOST, mini-CEX, Final FRCR	1,3,4
Assesses performance status	DOST, mini-CEX, Final FRCR, CbD	1,3
Behaviours		
See sections 1.3, 1.4 and 1.5	_	

4.15 Consent for biological therapy

To be able to consent patients for treatment with monoclonal antibodies, tyrosine kinase inhibitors, interferons, interleukins.

LCVCI	
Group A – Intermediate	Group B – Intermediate
Group C – Advanced	Group D - Advanced

Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Describes the acute and long term risks of treatment with monoclonal antibodies, tyrosine kinase inhibitors, interferons, interleukins	DOST, CbD, Final FRCR	1
Describes the aims of treatment and the prognosis	DOST, CbD, Final FRCR	1
Skills		
Explains about these issues and the risk/benefit ratio to the patient	DOST, mini-CEX, Final FRCR, PS	1,2,3,4
Completes the consent form accurately with the patient	DOST,mini-CEX, PS	1,2,3,4
Behaviours		
See sections 1.3, 1.4, 1.5, 1.11 and 1.14		

4.16 Initiating biological therapies

To be able to prescribe the first course of treatment with monoclonal antibodies, tyrosine kinase inhibitors, interferons and interleukins.

20101	
Group A – Core	Group B – Intermediate
Group C – Advanced	Group D – Advanced

Croup C Maranesa Croup D Maranesa			
Knowledge	Assessment Methods	GMP	
Describes the acute and long term side effects of the therapies	DOST, CbD	1,2	
Describes the importance of biochemical, haematological and radiological parameters in determining whether the treatment can be safely given	First FRCR, Final FRCR,	1,2	
Describes the supportive measures both pharmacological and non- pharmacological to treat toxic effects of therapy	DOST, CbD, First FRCR, Final FRCR,	1,2	
Skills			
Generates an appropriate systemic therapy prescription which is safe, accurate and meets local and national standards	DOST, MSF	1,2	
Behaviours			
See sections 1.3, 1.4 and 1.5			

4.17 Managing patients receiving biological therapies

To be able to manage patients undergoing treatment with monoclonal antibodies, tyrosine kinase inhibitors, interferons and interleukins.

LEV	CI.		

Group A – Core	Group B – Intermediate
Group C – Advanced	Group D - Advanced

Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Describes the acute and long term side-effects of these therapies	DOST, CbD, First FRCR, Final FRCR,	1,2
Describes how to assess tumour response	DOST, CbD, First FRCR, Final FRCR,	1
Skills		
Develops a management plan for the patient during the administration of the therapy including the management of side effects	DOST, CbD, Final FRCR	1,2,3
Prescribes supportive treatments	DOST, CbD, Final FRCR	1,2
Judges when to stop or continue treatment	DOST, CbD, Final FRCR, MSF	1,2,3,4
Behaviours		
See sections 1.3, 1.4 and 1.5		

4.18 Assessing patients for radiotherapy

To be able to assess patients for radical and palliative radiotherapy.		
Level		
Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Discusses basic physics relevant to radiotherapy, electromagnetic radiation and sub atomic particles and their interactions of with matter.	First FRCR	1
Discusses the indications for radiotherapy	DORPS, CbD, Final FRCR	1
Describes its side effects	DOST, CbD, First FRCR, Final FRCR	1,2
Evaluates the benefits and toxicity of treatment	DORPS, CbD, Final FRCR	1,2,3
Describes tests, procedures or other arrangements required prior to therapy	DORPS, CbD, Final FRCR	1,2
Skills		
Elicit the patient's wishes with regard to the aims of treatment	DORPS, mini-CEX, Final FRCR, PS	3
Performs an appropriate history and examination	DORPS, mini-CEX, Final FRCR	1,3,4
Assess performance status and use the information to inform the treatment plan	DORPS, mini-CEX, Final FRCR, CbD	1,3
Behaviours		
See sections 1.3, 1.4 and 1.5		

4.19 Consent for radiotherapy

4.19 Consent for radiotnerapy		
To be able to obtain informed consent from patients for radiotherapy.		
Level		
Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Describes the acute and long term risks of radiotherapy	DORPS, CbD, First FRCR, Final FRCR	1
Discusses the aims of treatment and the prognosis	DORPS, CbD, Final FRCR	1
Skills		
Explains these issues and the risk/benefit ratio with patients	DORPS, mini-CEX, Final FRCR, PS	1,2,3,4
Completes the informed consent form accurately with the patient	DORPS,mini-CEX, PS	1,2,3,4
Behaviours		
See sections 1.3, 1.4, 1.5, 1.11 and 1.14		

4.20 Radiotherapy treatment strategy

4.20 Radiotherapy treatment strategy		
To be able to develop a radiotherapy treatment strategy.		
Level		
Group A – Core Group B – Intermediate		
Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Describes the principles of radiation dosimetry, the physics of teletherapy beams (x-rays), electron beam physics and radiotherapy planning	First FRCR	1
Describes the patient position and immobilization technique	DORPS, Final FRCR	1
Describes the method of tumour localisation	DORPS, Final FRCR	1
Evaluates the possible radiotherapy modalities and beam arrangements	DORPS, Final FRCR	1
Skills		
Communicate effectively to the planning radiographers the imaging and treatment strategy	DORPS, MSF	1,2,3
Records all aspects of the planning process clearly	DORPS,CbD	1,2,3
Behaviours		
See sections 1.6, 1.7, and 1.9		

4.21 Radiotherapy treatment volume

To be able to determine the gross tumour volume (GTV), clinical target volume (CTV) and planning
target volume (PTV) as appropriate for radiotherapy.

target volume (PTV) as appropriate for radiotherapy.		
Level		
Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Interprets diagnostic imaging (including CT, PET and MRI	DORPS, Final FRCR	1
Describes the use of cross-sectional imaging in planning	DORPS, Final FRCR	1
Discusses the clinical and radiological parameters associated with planning 2-D conventional and 3-D conformal radiotherapy	DORPS, Final FRCR	1
Lists the tolerance of organs at risk.	DORPS,First FRCR Final FRCR	1,2
Skills		
Defines a treatment volume	DORPS, Final FRCR	1
Defines organs at risk and outlines them	DORPS, Final FRCR	1,2
Defines DVH based 3-D conformal planning constraints	DORPS, Final FRCR	1,2
Balances tumour control against potential damage to organs at risk	DORPS, Final FRCR	1,2
Behaviours		
See sections 1.5 and 1.6		

4.22 Radiotherapy treatment plan

To be able to evaluate a radiotherapy treatment plan.		
Level		
Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Describes the ICRU guidelines	DORPS, Final FRCR	1
Skills		
Assesses critically the dose distribution within the treatment volume and organs at risk	DORPS, Final FRCR	1,2
Evaluates whether a treatment plan is adequate and develops ways of improving an inadequate plan	DORPS, Final FRCR	1
Behaviours		
See sections 1.5		

4.23 Prescribing palliative radiotherapy

To be able to prescribe appropriate dose and fractionation schedule for palliative radiotherapy.			
Level			
Group A – Core	Group B – Intermediate		
Group C – Advanced	Group D – Advanced		
Knowledge		Assessment Methods	GMP
Describes the general tissue and population re	principles of radiobiology, including normal adiobiology	First FRCR	1
Describes dose/fractionation schedules in common use.		DORPS, Final FRCR	1
Skills			
Decides an appropriate treatment schedule according to stage of disease, performance status of patients and concomitant systemic therapy		DORPS, Final FRCR	1,2
Behaviours			
See sections 1.3, 1.4,1	.5 and 1.6		

4.24 Prescribing radical radiotherapy

TIZT TICSCHOING TOO	icai radiotilerapy		
To be able to prescribe app	ropriate dose and fractionation schedule	for radical radiotherapy.	
Level			
Group A – Intermediate Group C – Advanced	Group B – Intermediate Group D – Advanced		
Knowledge		Assessment Methods	GMP
Lists the parameters that should be included when writing a radiotherapy prescription		First FRCR	1
Describes dose/fractionation schedules in common use.		DORPS, Final FRCR	1
Skills			
Decides an appropriate treatment schedule according to stage of disease, performance status of patients and concomitant systemic therapy		DORPS, Final FRCR	1,2
Behaviours			
See sections 1.3, 1.4,1.5 an	nd 1.6		

4.25 Modifying radiotherapy for individual patients

To be able to modify treatment plans according to patient's individual needs, pre-morbid conditions etc.			
Level			
Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced			
Knowledge	Assessment Methods	GMP	
Describes normal tissue morbidity and its impact on target volume definition.	CbD, DORPS, First FRCR, Final FRCR	1,2	
Describes risks of re-treatment with radiation based on normal tissue tolerance limits	CbD, DORPS, First FRCR, Final FRCR	1,2	
Skills			
Judges how to modify treatment plans based on patient's comorbidity	CbD, DORPS, Final FRCR	1,2	
Assesses when re-treatment is acceptable and prescribes appropriate dose and fractionation	CbD, DORPS, Final FRCR	1,2	
Behaviours			
See sections 1.3, 1.4 and 1.5	·		

4.26 Principles of intensity-modulated radiotherapy (IMRT)

To be aware of the clinical implications of IMRT.		
Level		
Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced		
	Assessment	
Knowledge	Methods	GMP
Describes the theoretical benefits and risks of IMRT		GMP 1,2

4.27 Planning IMRT

7.27			
To be able to contribute to planning using IMRT.			
Level			
Group A – Advanced Group B – Advanced			
Group C – Advanced Group D – Advanced			
Knowledge	Assessment Methods	GMP	
Describes dose constraints for normal tissue	CbD, DORPS, First FRCR, Final FRCR	1,2	
Skills			
Define GTV, CTV and PTV as appropriate	DORPS, Final FRCR	1	
Behaviours			
See sections 1.3, 1.4,1.5 and 1.6			

4.28 Verifying radiotherapy treatments

To be able to verify a tr	reatment plan.		
Level			
Group A – Core	Group B – Intermediate		
Group C – Advanced	Group D - Advanced		
Knowledge		Assessment Methods	GMP
•	es that may be used to ensure that the on is correctly implemented	First FRCR	1,2
Describes the use of di	igitally reconstructed radiographs	CbD, DORPS, Final FRCR	1,2
Describes the use of portal imaging		CbD, DORPS, Final FRCR	1,2
Skills			
Assesses accuracy of p	patient set-up and recommends adjustments	CbD, DORPS, Final FRCR	1,2
Behaviours			
See section 1.5			

4.29 Principles of image-guided radiotherapy (IGRT)

To be aware of the clinical implications of IGRT.		
Level		
Group A – Core Group B – Intermediate Group C – Intermediate Group D – Advanced		
Knowledge	Assessment Methods	GMP
Discusses the indications and aims	DORPS, CbD, Final FRCR	1,2
Describes the methods available	DORPS, CbD, Final FRCR	1,2

4.30 Clinical implications of brachytherapy

To be aware of the clinical imp	lications of brachytherapy using seal	ed and unsealed sources.	
Level			
Group A – Intermediate Group C – Intermediate	Group B – Intermediate Group D – Advanced		
Knowledge		Assessment Methods	GMP
Describes the principles of rad brachytherapy	iotherapy physics related	DORPS, First FCR	1,2
Discusses the indications for a	nd aims of treatment	CbD, DORPS, First FRCR, Final FRCR	1,2
Describes the methods availab	ole	CbD, DORPS, First FRCR, Final FRCR	1,2
Describes the acute and long term toxicities and can discuss the organs at risk		CbD, DORPS, First FRCR, Final FRCR	1,2
Describes the principles of dose prescription		CbD, DORPS, First FRCR, Final FRCR	1,2
Describes the radiation protection issues		CbD, DORPS, First FRCR, Final FRCR	1,2
Recognises requirement for ARSAC certificate		CbD, DORPS, mini- CEX	1,2
Skills			
Applies radiation protection pri receiving brachytherapy	nciples when assessing patients	CbD, DORPS, Final FRCR	1,2
Behaviours			
See sections 1.3, 1.4,1.5 and	1.6		

4.31 Performing a brachytherapy procedure

To be able to perform a brachytherapy procedure using sealed sources.

 $\begin{array}{ll} \text{Group A - Advanced} & \text{Group B - Advanced} \\ \text{Group C - Advanced} & \text{Group D - Advanced} \end{array}$

Knowledge	Assessment Methods	GMP
Describes the relevant anatomy	CbD, DORPS, mini- CEX	1,2
Describes the appropriate investigations prior to and after treatment	CbD, DORPS, mini- CEX	1,2
Describes the patient position and any appropriate immobilisation techniques	CbD, DORPS, mini- CEX	1,2
Discusses the radiation protection issues.	CbD, DORPS, mini- CEX	1,2
Describes the concomitant therapies to reduce or treat toxicity	CbD, DORPS, mini- CEX	1,2
Recognises requirement for ARSAC certificate	CbD, DORPS, mini- CEX	1,2
Skills		
Assesses individual patients and balances the benefits against the risks	CbD, DORPS, mini- CEX	1,2,3,4
Elicit the patient's wishes with regard to the aims of treatment	CbD, DORPS, mini- CEX, PS	1,2,3,4
Explains the aims and risks to the patient and takes informed consent	CbD, DORPS, mini- CEX, PS	1,2,3,4
Communicate effectively with the radiographers, physicists, theatre staff, ward nurses with regards to the appropriate imaging and treatment strategy	CbD, DORPS, mini- CEX, MSF, PS	1,2,3,4
Records all aspects of the process clearly	CbD, mini-CEX, MSF	1,2,3
Performs the procedure correctly	CbD, mini-CEX, MSF	1,2
Prescribes the radiation dose balancing tumour control against potential damage to the organs at risk	CbD, DORPS, mini- CEX, MSF	1,2
Supports the patient through the treatment and side effects	CbD, mini-CEX, MSF, PS	1,2,3,4
Advises the patient, their relatives and staff with regard to radiation protection issues	CbD, DORPS, mini- CEX, MSF, PS	1,2,3,4
Liaises with the radiation protection advisor, including radiation protection supervisors and medical physics experts	CbD, DORPS, mini- CEX, MSF,	1,2,3
Behaviours		
See sections 1.3, 1.4,1.5, 1.6 and 1.9		

4.32 Prescribing brachytherapy using an unsealed source

To be able to prescribe brachytherapy using an unsealed source.		
Level		
Group A – Advanced Group B – Advanced Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Describes the appropriate investigations prior to and after treatment	CbD, DORPS, mini- CEX	1,2
Discusses the radiation protection issues	CbD, First FCR, mini- CEX	1,2
Describes the concomitant therapies to reduce or treat toxicity	CbD, DORPS, mini- CEX	1,2
Recognises the requirement for an ARSAC certificate	CbD, First FRCR, mini-CEX	1,2
Skills		
Assesses individual patients and balances the benefits against the risks	CbD, mini-CEX	1,2,3,4
Elicits the patient's wishes with regard to the aims of treatment	CbD, mini-CEX, PS	1,2,3,4
Explains the aims and risks to the patient and takes informed consent	CbD, mini-CEX, PS	1,2,3,4
Communicates effectively with the planning radiographers, physicists and ward nurses as appropriate the treatment strategy	CbD, DORPS, mini- CEX, MSF, PS	1,2,3,4
Records all aspects of the process clearly	CbD, DORPS, mini- CEX, MSF	1,2,3
Administers the isotope safely	CbD, mini-CEX, MSF	1,2
Prescribes the dose balancing tumour control against potential damage to the organs at risk	CbD, DORPS, mini- CEX, MSF	1,2
Supports the patient through the treatment and side effects	CbD, mini-CEX, MSF, PS	1,2,3,4
Advises the patient, their relatives and staff with regard to radiation protection issues	CbD, mini-CEX, MSF, PS	1,2,3,4
Liaises with the radiation protection advisor, including radiation protection supervisors and medical physics experts	CbD, mini-CEX, MSF,	1,2,3
Behaviours		
See sections 1.3, 1.4,1.5, 1.6 and 1.9		

4.33 Assessing and managing patients undergoing radiotherapy

4.00 Accessing and managing patients undergoing		
To be able to assess and manage patients undergoing radiotherapy.		
Level		
Group A – Core Group B – Core Group C – Core Group D – Advanced		
Knowledge	Assessment Methods	GMP
Describes early reactions to radiotherapy and their management	CbD, First FRCR, Final FRCR, mini-CEX	1,2
Skills		
Assesses and treats patients in an on-treatment clinic	CbD, Final FRCR, mini-CEX, PS	1,2
Behaviours		
See sections 1.3, 1.4 and 1.5		

4.34 Modifying a course of radiotherapy

To be able to modify a course of radiotherapy treatment for individual patients according to severity of reactions including adjustment for gaps in treatment.

reactions including adjustment for gaps in treatment.		
Level		
Group A – Intermediate Group B – Intermediate Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Discusses how radiobiological principles impact on radical radiotherapy	CbD, DORPS, First FRCR, Final FRCR	1,2
Lists possible strategies for dealing with treatment gaps	CbD, DORPS, First FRCR, Final FRCR	1,2
Skills		
Judges how to modify a course of radiotherapy treatment depending on acute toxicity and unplanned gaps in treatment	CbD, DORPS, Final FRCR,	1,2
Behaviours		
See sections 1.3, 1.4 and 1.5	·	

4.35 Assessing patients for combined modality therapy

To be able to assess patients for combined modality therapy.		
Level		
Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Discusses the interaction between chemotherapy and radiotherapy (before, during or following radiation)	CbD, DORPS, First FRCR	1,2
Discusses the circumstances in which combined modality therapy might be considered	CbD, DORPS, First FRCR, Final FRCR, mini-CEX	1,2
Skills		
Elicits the patient's wishes with regard to the aims of treatment	CbD, DORPS, Final FRCR, mini-CEX, PS	1,2,3,4
Discusses the side effects and risk/benefit ratio with patients	CbD, DORPS, Final FRCR, mini-CEX	1,2,3,4
Behaviours		
See sections 1.3, 1.4,1.5, 1.6 and 1.17	_	

4.36 Emerging techniques

To be able to discuss treatment with protons or neutrons			
Level			
Group A – Advanced Group B – Advanced Group C – Advanced Group D – Advanced			
Knowledge	Assessment Methods	GMP	
Knowledge Discusses the reasons why treatment with protons or neutrons treatments are sometimes desirable		GMP 1	

4.37 Obtaining informed consent for clinical trials and maintaining research records

To be able to consent patients for Phase II and Phase III trials and maintain appropriate research records.			
Level			
Group A – Core Group C – Advanced	Group B – Intermediate Group D – Advanced		
Knowledge		Assessment Methods	GMР
Discusses research eth	nics	CbD, mini-CEX	1,2,3
Describes Good Clinical Practice		CbD, mini-CEX	1,2,3
Skills			
Discusses option of en	tering a clinical trial with the patient	CbD, mini-CEX	1,2,3,4
Behaviours			
See sections 1.3, 1.14	and 1.16		

4.38 Diagnosing relapse

To be able to diagnose relapse.		
Level		
Group A – Core Group B – Intermediate Group C – Intermediate Group D – Advanced		
Knowledge	Assessment Methods	GMP
Describes the signs and symptoms, changes in tumours markers and imaging findings that may be associated with relapse	CbD, First FRCR, Final FRCR, mini-CEX	1,2
Skills		
Performs an appropriate history and examination	CbD, Final FRCR, mini-CEX, PS	1,2,3,4
Decides on appropriate investigations for patients suspected of having relapsed	CbD, Final FRCR, mini-CEX, PS	1,2
Interprets imaging (X-rays, CT, MRI, PET)	CbD, Final FRCR, mini-CEX,	1,2
Behaviours		
See sections 1.2, 1.3, 1.4 and 1.5		

4.39 Developing a management plan for patients whose disease has relapsed

To be able to develop a management plan for patients whose disease has relapsed.			
Level			
Group A – Core	Group B – Intermediate		
Group C – Advanced	Group D – Advanced		
Knowledge		Assessment Methods	GMP
radiotherapy, chemoth kinase inhibitors, interf	surgery, interventional radiology, erapy, monoclonal antibodies, tyrosine erons, interleukins, symptom control and ats with relapsed disease	CbD, Final FRCR, mini-CEX	1,2
Skills			
Elicits the patient's wis	hes with regard to the aims of treatment	CbD, Final FRCR, mini-CEX	1,2,3,4
Behaviours			
See sections 1.3, 1.4,	1.5, 1.6 and 1.11		

4.40 Assessing patients for second and further lines of systemic anticancer therapy

To be able to assess patients for appropriate second and further lines of chemotherapy, monoclonal antibodies, tyrosine kinase inhibitors, interferons or interleukins.

Group A – Intermediate	Group B – Intermediate
Group C – Advanced	Group D – Advanced

Level

Knowledge	Assessment Methods	GMP
Describes the molecular biology of chemotherapy drug resistance	DOST, First FCR	
Discusses the role of 2 nd and further lines of chemotherapy and monoclonal antibodies, tyrosine kinase inhibitors, interferons, interleukins	CbD, First FRCR, Final FRCR, mini-CEX	1,2
Discusses different patient motives (coping, survival enhancement, improvement of quality of life)	CbD, First FRCR, Final FRCR, mini- CEX, PS	1,2
Skills		
Assesses patient's fitness for treatments e.g., by performance status	CbD, DOST, Final FRCR, mini-CEX, PS	1,2,3,4
Prescribes common therapeutic regimes	CbD, DOST, Final FRCR, mini-CEX, PS	1,2
Assesses whether the outcomes of the therapy are meeting the patient's needs and discusses this with them	CbD, DOST, Final FRCR, mini-CEX, PS	1,2,3,4
Behaviours		
See sections 1.3, 1.4, 1.5, 1.6 and 1.11		

4.41 Adjusting a chemotherapy regimen according to patient fitness

To be able to adjust choice of second and further lines of chemotherapy regimen according to patient fitness.

Level	
Group A – Intermediate	Group B – Intermediate
Group C – Advanced	Group D - Advanced

Group C - Advanced Group D - Advanced		
Knowledge	Assessment Methods	GMP
Discusses the problems associated with treatment regimens in pre- treated patients, the elderly, those with comorbidity and patients with lower performance status	CbD, DOST, Final FRCR, mini-CEX	1,2,3
Skills		
Modifies treatment plan appropriately for individual patients	CbD, DOST, Final FRCR	1,2
Judges when to continue or stop treatment	CbD, DOST, Final FRCR	1,2
Behaviours		
See sections 1.3, 1.4, 1.5, 1.6 and 1.11		

4.42 Assessing response to second and subsequent lines of chemotherapy

To be able to assess response to second and subsequent lines of chemotherapy.		
Level		
Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Discusses the aims of treatment	CbD, DOST, Final FRCR	1,2
Skills		
Assesses response according to RECIST criteria	CbD, DOST, Final FRCR	1,2
Behaviours		
See sections 1.3, 1.4 and 1.5		

4.43 Recognising when further chemotherapy is inappropriate

To be able to recognise when further or continuing chemotherapy is inappropriate.		
Level		
Group A – Intermediate Group B – Intermediate Group C – Advanced Group D – Advanced		
Knowledge	Assessment Methods	GMP
Discusses the palliative options available to a patient who is not responding to /tolerating treatment	CbD, Final FRCR, mini-CEX	1,2
Skills		
Communicates bad news to the patient and their relatives	CbD, DOST, Final FRCR, mini-CEX, PS	1,2,3,4
Negotiates stopping treatment with the patient and their relatives	CbD, DOST, Final FRCR, mini-CEX, PS	1,2,3,4
Organises palliative supportive care	CbD, DOST, Final FRCR, mini-CEX	1,2
Behaviours		
See sections 1.3, 1.4, 1.5, 1.6 and 1.11	·	

4.44 Assessing patients with relapsed cancer for palliative radiotherapy

To be able to assess patients with relapsed cancer for palliative radiotherapy.			
Level			
Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced			
Knowledge	Assessment Methods	GMP	
Discusses the radiobiological consequences of retreatment if appropriate	CbD, DORPS, First FRCR, Final FRCR, mini-CEX	1,2	
Skills			
Elicits the patient's wishes with regard to the aims of treatmen	CbD, DORPS, nt Final FRCR, mini- CEX, PS	1,2,3,4	
Discusses the role of radiotherapy and risk/benefit with individual patients	CbD, DORPS, Final FRCR, mini- CEX, PS	1,2,3,4	
Behaviours			
See sections 1.3, 1.4, 1.5 and 1.11			

4.45 Identifying when patients with relapsed disease require referral to another specialty

To be able to identify when patients with relapsed disease require referral to another speciality.			
Level			
Group A – Core Group B – Intermediate			
Group C – Advanced Group D – Advanced			
Knowledge	Assessment Methods	GMP	
Describes the indications for surgical, radiological intervention and high dose chemotherapy with autologous or allogeneic transplantation	CbD, Final FRCR,	1,2	
Skills			
Elicits the patient's wishes with regard to the aims of treatment	CbD, Final FRCR, mini-CEX, PS	1,2,3,4	
Develops an appropriate treatment plan for individual patients	CbD, Final FRCR, mini-CEX, PS	1,2,3,4	
Behaviours			
See sections 1.3, 1.4, 1.5, 1.6 and 1.9			

4.46 Managing physical symptoms of patients with relapsed cancer

To be able to manage the physical symptoms of patients with relapsed cancer. Level Group A - Core Group B - Core Group C - Core Group D - Advanced Assessment **GMP** Knowledge **Methods** Outlines the clinical pharmacology of analgesics, steroids and anti-CbD, First FRCR 1,2 emetics. Discusses the differential diagnosis of symptoms in patients with CbD, Final FRCR, relapsed cancer both due to metastatic and the non-metastatic 1,2 mini-CEX manifestations of malignancy CbD, Final FRCR, Describes the appropriate investigations 1,2 mini-CEX CbD, Final FRCR, Describes the treatment options available 1,2 mini-CEX **Skills** CbD, Final FRCR, Performs a focused history and examination 1,2,3,4 mini-CEX, PS CbD, Final FRCR, Discusses the options with the patient 1,2,3,4 mini-CEX, PS Advises the patient as to the management plan most likely to CbD, Final FRCR, 1,2,3,4 improve their symptoms mini-CEX, PS Prescribes drugs for palliation of symptoms including in the last few CbD, Final FRCR, 1,2,3,4 mini-CEX days of life **Behaviours** See sections 1.3, 1.4, 1.5, 1.6, 1.9 and 1.11

4.47 Providing psychological support for patients with relapsed cancer and their families

To be able to provide psychological support for patients with relapsed cancer and their families.			
Level			
Group A – Core Group B – Core Group C – Core Group D – Advanced			
Knowledge	Assessment Methods	GMP	
Discusses the process of accepting a terminal prognosis, grieving and bereavement	CbD, Final FRCR, mini-CEX	1,2	
Discusses the role of the family, primary care, hospice, support groups palliative care teams, psychologist	CbD, Final FRCR, mini-CEX	1,2,3	
Describes the indications for and side effects of antidepressants and psychotropic medication	CbD, Final FRCR, mini-CEX	1,2	
Describes cultural variation in ways of dealing with bereavement	CbD, Final FRCR, mini-CEX	1,2	
Skills			
Supports patient and family to discuss the impact of the prognosis and to cope with denial, anger, and emotional distress	CbD, Final FRCR, mini-CEX, PS	1,2,3,4	
Negotiates satisfactory outcome to requests by relatives for collusion to hide the prognosis from the patient	CbD, Final FRCR, mini-CEX, PS	1,2,3,4	
Liaises with other professionals to develop a management plan	CbD, Final FRCR, mini-CEX, MSF, PS	1,2,3,4	
Prescribes appropriate medication	CbD, Final FRCR, mini-CEX	1,2	
Behaviours			
See sections 1.3, 1.4, 1.5, 1.6, 1.9, 1.11, 1.12 and 1.13			

4.48 Co-ordinating social/financial support

To be able to co-ordinate social/financial support for patients with relapsed cancer.			
Level			
Group A – Core	Group B – Core		
Group C – Core	Group D – Advanced		
Knowledge		Assessment Methods	GMP
	other professional groups – social workers, s, physiotherapists, GPs, district nurses,	CbD, Final FRCR, mini-CEX	1,2,3
Describes how to access financial support – attendance allowance under special rules		CbD, Final FRCR, mini-CEX	1,2,3
Skills			
Negotiates with the pa develop an agreed pag	tient, family and other professional groups to ckage of care	CbD, Final FRCR, mini-CEX, PS	1,2,3,4
Behaviours			
See sections 1.3, 1.4,	1.5, 1.6, 1.9 and 1.11		

4.49 Making clinical decisions in situations of uncertainty

	ecisions in situations of uncertainty.	•	
Level			
Group A – Advanced Group C – Advanced	Group B – Advanced Group D – Advanced		
Knowledge		Assessment Methods	GMP
Discusses the evidence base		CbD, Final FRCR, mini-CEX	1,2
Identifies the areas of uncerta	ninty and methods of decreasing this	CbD, Final FRCR, mini-CEX	1,2
Skills			
Evaluates the possible treatm	ent options	CbD, Final FRCR, mini-CEX	1,2
Discusses options with patien benefits and side effects	t and advises on the predicted	CbD, Final FRCR, mini-CEX, PS	1,2,3,4
Supports the patient to make	a decision	CbD, Final FRCR, mini-CEX, PS	1,2,3,4
Behaviours			
See sections 1.3, 1.4, 1.5, 1.6	s, 1.11, 1.12 and 1.13		